Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Haematol ; 120(1): 36-46, 2008.
Article in English | MEDLINE | ID: mdl-18797163

ABSTRACT

Post-transplant lymphoproliferative disorders (PTLD) is a serious complication after solid organ transplantation. Reduction of immunosuppression (RI) alone is not able to control the disease. We report a prospective analysis of 30 patients with PTLD after heart or kidney transplantation. Only 5 of 30 patients, treated solely with RI, obtained a complete response. Five patients were treated heterogeneously; in the remaining 20, the efficacy and safety of a weekly anthracycline-based chemotherapy were assessed. Sixteen patients obtained a complete remission. One death was related to treatment. With a median follow-up of 36 months, 3-year overall survival was 63.3% and 57% for the entire group and the chemotherapy-treated group, respectively. Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival.


Subject(s)
Heart Transplantation/adverse effects , Kidney Transplantation/adverse effects , Lymphoproliferative Disorders/etiology , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols , Female , Hodgkin Disease/therapy , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Lymphoma, Non-Hodgkin/therapy , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/drug therapy , Male , Middle Aged , Neoplasms, Second Primary/etiology , Prospective Studies , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...